These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 17701721)

  • 1. Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors.
    Di Giambenedetto S; Bacarelli A; Pinnetti C; Colafigli M; Prosperi M; Gatti G; Cauda R; De Luca A
    Scand J Infect Dis; 2007; 39(9):813-8. PubMed ID: 17701721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
    Marcelin AG; Flandre P; Molina JM; Katlama C; Yeni P; Raffi F; Antoun Z; Ait-Khaled M; Calvez V
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4251-7. PubMed ID: 18852278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
    Maillard A; Chapplain JM; Tribut O; Bentué-Ferrer D; Tattevin P; Arvieux C; Michelet C; Ruffault A
    J Clin Virol; 2007 Feb; 38(2):131-8. PubMed ID: 17208042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir.
    Masquelier B; Assoumou KL; Descamps D; Bocket L; Cottalorda J; Ruffault A; Marcelin AG; Morand-Joubert L; Tamalet C; Charpentier C; Peytavin G; Antoun Z; Brun-Vézinet F; Costagliola D;
    J Antimicrob Chemother; 2008 Jun; 61(6):1362-8. PubMed ID: 18390885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
    Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
    J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fosamprenavir calcium plus ritonavir for HIV infection.
    Torres HA; Arduino RC
    Expert Rev Anti Infect Ther; 2007 Jun; 5(3):349-63. PubMed ID: 17547501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naïve patients with HIV-1 infection.
    Calza L; Manfredi R; Pocaterra D; Chiodo F
    Int J STD AIDS; 2008 Aug; 19(8):541-4. PubMed ID: 18663041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.
    Gianotti N; Galli L; Danise A; Hasson H; Boeri E; Lazzarin A; Castagna A
    J Med Virol; 2006 Dec; 78(12):1537-41. PubMed ID: 17063520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.
    Raguin G; Chêne G; Morand-Joubert L; Taburet AM; Droz C; Le Tiec C; Clavel F; Girard PM;
    Antivir Ther; 2004 Aug; 9(4):615-25. PubMed ID: 15456093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
    Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
    J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance.
    de Mendoza C; Valer L; Bacheler L; Pattery T; Corral A; Soriano V
    AIDS; 2006 Apr; 20(7):1071-4. PubMed ID: 16603864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes.
    De Luca A; Vendittelli M; Baldini F; Di Giambenedetto S; Trotta MP; Cingolani A; Bacarelli A; Gori C; Perno CF; Antinori A; Ulivi G
    Antivir Ther; 2004 Aug; 9(4):583-93. PubMed ID: 15456090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients.
    King MS; Rode R; Cohen-Codar I; Calvez V; Marcelin AG; Hanna GJ; Kempf DJ
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3067-74. PubMed ID: 17576846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.
    Kempf DJ; Isaacson JD; King MS; Brun SC; Sylte J; Richards B; Bernstein B; Rode R; Sun E
    Antivir Ther; 2002 Sep; 7(3):165-74. PubMed ID: 12487383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.
    Torti C; Uccelli MC; Quiros-Roldan E; Gargiulo F; Tirelli V; Lapadula G; Regazzi M; Pierotti P; Tinelli C; De Luca A; Patroni A; Manca N; Carosi G
    J Clin Virol; 2006 Apr; 35(4):414-9. PubMed ID: 16280255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors.
    Fox ZV; Geretti AM; Kjaer J; Dragsted UB; Phillips AN; Gerstoft J; Staszewski S; Clotet B; von Wyl V; Lundgren JD
    AIDS; 2007 Oct; 21(15):2033-42. PubMed ID: 17885293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens.
    Loutfy MR; Raboud JM; Walmsley SL; Saskin R; Montaner JS; Hogg RS; Thompson CA; Harrigan PR
    Antivir Ther; 2004 Aug; 9(4):595-602. PubMed ID: 15456091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
    Hill A; Marcelin AG; Calvez V
    HIV Med; 2009 Nov; 10(10):620-6. PubMed ID: 19601995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Lopinavir/ritonavir in HIV-infected patient with long-term virological failure: immunovirological response and tolerance in 121 patients of the ANRS CO8 Aproco-Copilote cohort].
    Brunet-François C; Taieb A; Masquelier B; Le Moing V; Lewden C; Dellamonica P; Cuzin L; Allavena C; Spire B; Chêne G; Raffi F;
    Med Mal Infect; 2007 Mar; 37(3):172-7. PubMed ID: 17239554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients.
    Marcelin AG; Cohen-Codar I; King MS; Colson P; Guillevic E; Descamps D; Lamotte C; Schneider V; Ritter J; Segondy M; Peigue-Lafeuille H; Morand-Joubert L; Schmuck A; Ruffault A; Palmer P; Chaix ML; Mackiewicz V; Brodard V; Izopet J; Cottalorda J; Kohli E; Chauvin JP; Kempf DJ; Peytavin G; Calvez V
    Antimicrob Agents Chemother; 2005 May; 49(5):1720-6. PubMed ID: 15855487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.